<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01990846</url>
  </required_header>
  <id_info>
    <org_study_id>AIT02-1002</org_study_id>
    <nct_id>NCT01990846</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, and PK of Escalating Doses of Flufirvitide-3 Dry Powder for Inhalation in Healthy Subjects</brief_title>
  <official_title>A Phase 1, Randomized, Double-blind, Placebo-controlled Assessment of the Safety, Tolerability and Pharmacokinetics of Escalating Single and Repeat Doses of Flufirvitide-3 Dry Powder for Inhalation in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Autoimmune Technologies, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Autoimmune Technologies, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety, tolerability and pharmacokinetics (PK) of single,and repeat
      escalating doses of FF-3 dry powder administered via inhalation in healthy adult subjects
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Actual">February 2015</completion_date>
  <primary_completion_date type="Actual">February 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in adverse events from Baseline</measure>
    <time_frame>8 days</time_frame>
  </primary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">68</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>Flufirvitide-3 dose level 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose administration for dose level 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Flufirvitide 3-Dose level 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose administration for Dose Level 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single Dose administration Placebo for Flufirvitide-3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Flufirvitide-3 Dose level 1- Repeat dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Repeat dose administration for five days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Flufirvitide-3-Dose level 2 Repeat dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Repeat dose administration for 5 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo for Flufirvitide-3 Repeat dose</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Repeat dose administration for 5 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Flufirvitide 3</intervention_name>
    <arm_group_label>Flufirvitide-3 dose level 1</arm_group_label>
    <arm_group_label>Flufirvitide 3-Dose level 2</arm_group_label>
    <arm_group_label>Flufirvitide-3 Dose level 1- Repeat dose</arm_group_label>
    <arm_group_label>Flufirvitide-3-Dose level 2 Repeat dose</arm_group_label>
    <other_name>FF-3</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for Flufirvitide-3</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Placebo for Flufirvitide-3 Repeat dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy male and non-pregnant, non-lactating female subjects of 18 to 50 years of age
             inclusive.

          2. Body Mass Index (BMI) of 18 to 30 kg/m2 inclusive and body weight of 50 to 100 kg
             inclusive.

          3. Normal spirometry values at Screening and Baseline defined as forced vital capacity
             (FVC) and forced expiratory volume in one second (FEV1) greater than 80% predicted or
             above the LLN and the FEV1/FVC ratio greater than 70%. Results of FEV1 and FVC must be
             reproducible (± 5%) between Screening and Baseline.

          4. Post-menopausal women with amenorrhea for at least 2 years will be eligible (confirmed
             by follicle stimulating hormone [FSH] test).

          5. Females of childbearing potential must use acceptable birth control methods throughout
             the study and for 30 days after the last dose of the IMP:

          6. Male subjects:

               1. Must agree to use a condom (or diaphragm plus spermicide in female partner) from
                  the time of the first dose of IMP through 90 days after the last dose.

               2. Must agree to not donate sperm for 90 days after the last dose of IMP.

               3. Vasectomies in males for 6 months minimum prior to the first dose of the IMP are
                  an acceptable form of contraception.

               4. Males who claim abstinence as their method of contraception are allowed provided
                  they agree to use a barrier method (diaphragm plus spermicide in female partner
                  or condom) should they become sexually active from screening to 90 days after the
                  last dose of IMP.

          7. Willing and able to provide written informed consent and provide authorization for use
             of protected health information (HIPAA).

          8. Willing and able to adhere to the lifestyle guideline restrictions outlined in the
             protocol.

          9. Willing and able to be confined to the CRU as required by the protocol.

        Exclusion Criteria

          1. Evidence of or history of clinically significant oncologic, pulmonary, hepatic,
             gastrointestinal, cardiovascular, hematologic, metabolic, neurological, immunologic,
             nephrologic, endocrine, or psychiatric disease, or current clinically significant
             infection.

          2. History and/or presence of asthma at Screening or Baseline; presence of active
             rhinitis or sinusitis at Screening or Baseline.

          3. Clinically significant nasal abnormalities including nasal septum deviation, septum
             perforations, or polyps, history of recurrent epistaxis, history of sinus surgery
             and/or persistent hypertrophic inferior turbinates.

          4. Clinically significant abnormalities at Screening or Baseline in safety laboratory
             tests, ECGs, or spirometry.

          5. Inability to perform spirometry according to the 2005 American Thoracic Society (ATS)
             acceptability and repeatability standards.

          6. History of significant nasal irritation from use of nasal sprays or drops.

          7. Corrected QT interval (QTc) greater than 450 msec for males and 470 msec for females
             as corrected by the Fridericia formula.

          8. History of drug or alcohol abuse within the past 2 years; current excessive user of
             alcohol defined as regular weekly intake of greater than 15 units for male subjects
             and 10 units for female subjects. One unit equals 25 mL spirits, 125 mL wine or 250 mL
             beer.

          9. Tobacco users (includes users who stopped smoking £90 days prior to the screening
             evaluation). [Note: &quot;Tobacco use&quot; includes smoking and the use of snuff and chewing
             tobacco, and other nicotine or nicotine containing products.]

         10. Received an IMP or participated in another research study within 30 days of the first
             dose of the IMP for this study.

         11. Participated in a previous investigational study of FF3.

         12. History of influenza vaccination with a live vaccine within 7 days or with an
             attenuated vaccine within 14 days of the first dose of IMP.

         13. Use of prescription drugs within 14 days prior to the first dose of IMP, excepting
             oral contraceptives.

         14. Received any non-prescription medications, vitamins, or dietary supplements within 7
             days of administration of the first dose of IMP, unless prior approval is granted by
             both the Principal Investigator and the Medical Monitor. Excluded from this list is
             intermittent use of acetaminophen £2 g/day or ibuprofen £1200 mg/day. Herbal
             supplements must be discontinued 14 days prior to the first dose of IMP.

         15. Use of any antihistamines and/or decongestants within 30 days or nasal corticosteroids
             within 3 months prior to the first dose of IMP.

         16. Consumed alcohol within 72 hours of Day -1 or have a positive alcohol test at
             Screening or admission to the CRU.

         17. Subjects who consumed grapefruit juice or juices containing grapefruit or ate
             grapefruit or ate Seville oranges within 7 days prior to the first dose of IMP.

         18. Excessive intake of caffeine-containing foods or beverages (more than 5 units or
             equivalent per day) within 48 hours prior to the admission to the study center (Day
             1). One caffeine unit is contained in the following items: 1 (6 oz) cup of coffee, 2
             (12 oz) cans of cola, 1 (12 oz) glass of tea, ½ (4 oz) cup of energy drink (e.g., Red
             Bull) or 3 (1 oz) chocolate bars.

         19. Positive serum pregnancy test at the Screening Visit or positive urine pregnancy test
             on Day 1 (females only).

         20. Positive test for human immunodeficiency virus (HIV), hepatitis B surface antigen
             (HBsAg) or anti-hepatitis C virus (anti-HCV) at the Screening Visit.

         21. Positive urine drug test at the Screening Visit or at admission to the CRU.

         22. Likelihood of requiring treatment during the study period with drugs not permitted by
             the study protocol.

         23. Subjects who have donated blood or experienced other significant blood loss within 56
             days of screening for the study.

         24. Subjects with hemoglobin (Hb) &lt;11 g/dL
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Spartanburg Medical Research</name>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <zip>29303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 18, 2013</study_first_submitted>
  <study_first_submitted_qc>November 18, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 25, 2013</study_first_posted>
  <last_update_submitted>March 9, 2015</last_update_submitted>
  <last_update_submitted_qc>March 9, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 11, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>antiviral, influenza</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

